Microwave Treatment of Common and Plantar Warts (NCT05371834) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Microwave Treatment of Common and Plantar Warts
United States119 participantsStarted 2022-07-06
Plain-language summary
This is a multi-center, open, randomized, parallel-group, controlled, blind-assessed trial of approximately 124 subjects that require treatment for up to 5 common or plantar warts. Subjects will be randomized to one of two treatment groups: Microwave Treatment (Swift® system) or Cryotherapy.
Who can participate
Age range18 Years – 64 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Provision of signed and dated informed consent form;
✓. Stated willingness to comply with all study procedures and availability for the duration of the study;
✓. Age 18-64 years inclusive;
✓. A minimum of one clinically significant common wart (usually found on hands, knees and elbows), or one plantar wart. Note: the warts for treatment cannot be a mixture of common and plantar warts;
✓. Subject's common warts must measure between 3mm-10mm or for plantar warts, measure between 3mm-20mm, inclusive;
✓. If currently receiving treatment for common or plantar warts, agree to stop their current medication for at least 28 days prior to the start of study treatment;
✓. Agrees to refrain from using any other wart removal products or treatments during the study period;
✓. Agrees to not take any non-steroidal anti-inflammatory drugs (NSAIDs) or antihistamines within a 12-hour period prior to and after randomized treatment;
Exclusion criteria
✕. Pregnancy or breast feeding;
✕. Mosaic warts for treatment;
✕. Warts (common or plantar) that have been reported by the subject as present for more than 5 years (relates to any wart present and which may not necessarily be treated in this study);
What they're measuring
1
Clearance of all treated warts, each of which is defined as "resolved" or "not resolved" based on the classification by the blinded site investigator assessing the treated warts at three months post final treatment (up to 5 warts in total).